section name header

Pronunciation

LIR-a-GLOO-tide

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: glucagon like peptide 1 glp 1 receptor agonists

Indications

REMS


Victoza

Saxenda

Saxenda

Action

  • Acts as an acylated human glucagon-like peptide-1 (GLP-1, an incretin) receptor agonist; increases intracellular cyclic AMP leading to insulin release when glucose is elevated, which then subsides as blood glucose decreases toward euglycemia. Also decreases glucagon secretion and delays gastric emptying. Also helps to suppress appetite, leading to decreased caloric intake.
Therapeutic effects:
  • Improved glycemic control.
  • Reduction in body weight.
  • Reduction in cardiovascular death, nonfatal MI, or nonfatal stroke.

Pharmacokinetics

Absorption: 55% absorbed following SUBQ injection.

Distribution: Unknown.

Protein Binding: >98%.

Metabolism/Excretion: Endogenously metabolized.

Half-Life: 13 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
SUBQwithin 4 wk
within 2 wk
8 wk
40 wk
unknown



in A1c.

in body weight.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Victoza

Saxenda

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Saxenda, Victoza